Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 48 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMAGIVES from Huy, company number BE0526969524, closed financial year 2025 with a result of € -276 after tax. For that financial year PHARMAGIVES recorded a gross margin of € 147,548 and equity of € 3,709. Compared with financial year 2024, the result moved from € -298 to € -276. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 3,709
▼ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -276
▲ 7 % less loss than in 2024
Profit after tax over the fiscal year.
€ 24,027
▼ 10% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -8,691.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 111,991
▲ 10% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 29,468
▲ 131% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 163,638
▲ 12% vs 2024
€ 66,336 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 140,637
▲ 11% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 19,420
▲ 3% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 139,465 | € 190,171 | € 144,324 | € 147,548 | ▲ 2% |
| Profit after taxes | € -5,650 | € 38,265 | € -298 | € -276 | ▲ € 22 |
| Equity | € -33,982 | € 4,283 | € 3,985 | € 3,709 | ▼ 7% |
| Total debts | € 428,120 | € 376,016 | € 302,057 | € 339,816 | ▲ 13% |
| Cash | € 35,462 | € 8,475 | € 26,689 | € 24,027 | ▼ 10% |
| Land & buildings | € 24,419 | - | - | - | |
| Retained profit | € -46,382 | € -8,117 | € -8,415 | € -8,691 | ▼ € 276 |
| Bank debt | € 244,605 | € 194,504 | € 145,832 | € 163,638 | ▲ 12% |
| Balance sheet total | € 394,137 | € 380,299 | € 306,042 | € 343,524 | ▲ 12% |
| Employees (FTE) | 1.2 | 1.6 | - | - |
Key figures of PHARMAGIVES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMAGIVES?
What happened at PHARMAGIVES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 276. Source: NBB ↗
- Viviane Fontaine became a director. NBB
- New establishment in Huy. KBO
- Start of the company according to the CBE. KBO
In short
From € 5,650 loss in 2022 to € 276 loss in 2025.
Paid € 4,655 in corporate taxes since 2022.
Best year ever: 2023, with € 38,265 profit.
On average € 118,900 of value added per employee in 2023.
A new publication or filing at PHARMAGIVES? We notify you, reason included.
Follow PHARMAGIVESDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMAGIVES is Viviane Fontaine. Viviane Fontaine is also behind Immogives.
Directors
According to the 2025 annual accounts
since 2020
Establishments
Establishment units
Physical locations of this company
Chaussée d'Andenne 60
4500 Huy
Chaussée d'Andenne 51
4500 Huy
Active since 22 April 2013
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0526.969.524
- VAT number
- BE 0526.969.524
- Registered office
- Chaussée d'Andenne 60, 4500 Huy
- Names & denominations
- PHARMAGIVES
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 April 2013
- Peppol
- Active · Active since 11 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Schoonheidsverzorging en andere schoonheidsbehandelingen
Activiteiten van kuuroorden, sauna’s en stoombaden
Schoonheidsverzorging
Sauna's, solaria, baden enz.